Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dornase Alfa

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Pulmozyme

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2019 Revenue in Millions : 774

    2018 Revenue in Millions : 761

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 715

    2019 Revenue in Millions : 837

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 609

    2020 Revenue in Millions : 681

    Growth (%) : -12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 594

    2021 Revenue in Millions : 609

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 524

    2022 Revenue in Millions : 594

    Growth (%) : -17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Disease

    Currency : USD

    2014 Revenue in Millions : 4.40%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Disease

    Currency : USD

    2015 Revenue in Millions : 603

    2014 Revenue in Millions : 659

    Growth (%) : 9%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2016 Revenue in Millions : 678

    2015 Revenue in Millions : 645

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2017 Revenue in Millions : 774

    2016 Revenue in Millions : 726

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2018 Revenue in Millions : 746

    2017 Revenue in Millions : 737

    Growth (%) : 1%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF